MT-302

About Create Medicines

Create Medicines is developing a novel class of immunotherapies via its proprietary in vivo CAR platform, which uses mRNA-LNP formulations to program multiple immune cell types directly in the body. This approach seeks to overcome the manufacturing complexity, cost, and time constraints of ex vivo cell therapies. The company has generated first-in-human clinical data confirming mechanism of action and is advancing a pipeline with programs in Phase 1 and Phase 2 for solid tumors and hematologic malignancies. Founded in 2021 and based in Boston, CREATE is a private, pre-revenue company positioning itself at the forefront of scalable, off-the-shelf cell therapy.

Therapeutic Areas